Drug-Device Combination Could Help Treat Stroke
By HospiMedica International staff writers Posted on 18 Nov 2015 |

Image: TEB combine with SA-NT therapy dissolves blood clots (Photo courtesy of Wyss Institute for Biologically Inspired Engineering).
A novel therapeutic approach combines a temporary endovascular bypass (TEB) with clot-busting nanoparticles to restore blood flow to obstructed vessels.
Developed by researchers at the Wyss Institute for Biologically Inspired Engineering (Boston, MA, USA), the New England Center for Stroke Research (NECSTR; Worcester, MA, USA) and other institutions, the drug-device combination is designed to quickly re-vascularize a vessel obstructed by a blood clot. The process involves an intra-arterial stent used to open a TEB, restoring enough blood flow to trigger a shear-activated nanotherapeutic (SA-NT) agent to dissolve the blood clot.
The SA-NT agent is composed of an aggregate of biodegradable nanoparticles coated with recombinant tissue plasminogen activator (r-tPA). As blood flow increases at the TEB location, the shear force grows, and the SA-NT agent reacts to it by releasing the r-tPA-coated nanoparticles in the partially occluded blood vessels. Hemodynamic stress causes the r-tPA to concentrate at the occlusion site, binding to the clot and dissolving it, thus providing high recanalization rates while reducing vascular injury.
After the blood clot is fully dissolved, the stent is re-sheathed and harmlessly removed from the vessel. If during the process any clot fragments break off and travel away through the circulatory system, the SA-NT drug-coated nanoparticles will remain bound to them and continue to dissolve them locally wherever they go. In clinically relevant large animal studies, the TEB/SA-NT combination worked very efficiently, dissolving clots that fully occluded brain blood vessels of the same size found in humans. The study was published on October 22, 2015, in Stroke.
“What's progressive about this approach is that the temporary opening of a tiny hole in the clot, using a stent device that is already commonly used clinically, results in a local rise in mechanical forces that activate the nanotherapeutic to deploy the clot-busting drug precisely where it can best do its job,” said senior author Donald Ingber, MD, PhD, of the Wyss Institute for Biologically Inspired Engineering.
“This has been a great collaboration between experts in the field of treating stroke and experts in mechanobiology and bioengineering,” said co-first author Netanel Korin, PhD, former Wyss Technology development fellow and current assistant professor in biomedical engineering at the Israel Institute of Technology (Technion; Haifa, Israel). “We hope that one day it will have a positive impact on patients suffering from a range of medical crises resulting from blood clot occlusions.”
Related Links:
Wyss Institute for Biologically Inspired Engineering
New England Center for Stroke Research
Israel Institute of Technology
Developed by researchers at the Wyss Institute for Biologically Inspired Engineering (Boston, MA, USA), the New England Center for Stroke Research (NECSTR; Worcester, MA, USA) and other institutions, the drug-device combination is designed to quickly re-vascularize a vessel obstructed by a blood clot. The process involves an intra-arterial stent used to open a TEB, restoring enough blood flow to trigger a shear-activated nanotherapeutic (SA-NT) agent to dissolve the blood clot.
The SA-NT agent is composed of an aggregate of biodegradable nanoparticles coated with recombinant tissue plasminogen activator (r-tPA). As blood flow increases at the TEB location, the shear force grows, and the SA-NT agent reacts to it by releasing the r-tPA-coated nanoparticles in the partially occluded blood vessels. Hemodynamic stress causes the r-tPA to concentrate at the occlusion site, binding to the clot and dissolving it, thus providing high recanalization rates while reducing vascular injury.
After the blood clot is fully dissolved, the stent is re-sheathed and harmlessly removed from the vessel. If during the process any clot fragments break off and travel away through the circulatory system, the SA-NT drug-coated nanoparticles will remain bound to them and continue to dissolve them locally wherever they go. In clinically relevant large animal studies, the TEB/SA-NT combination worked very efficiently, dissolving clots that fully occluded brain blood vessels of the same size found in humans. The study was published on October 22, 2015, in Stroke.
“What's progressive about this approach is that the temporary opening of a tiny hole in the clot, using a stent device that is already commonly used clinically, results in a local rise in mechanical forces that activate the nanotherapeutic to deploy the clot-busting drug precisely where it can best do its job,” said senior author Donald Ingber, MD, PhD, of the Wyss Institute for Biologically Inspired Engineering.
“This has been a great collaboration between experts in the field of treating stroke and experts in mechanobiology and bioengineering,” said co-first author Netanel Korin, PhD, former Wyss Technology development fellow and current assistant professor in biomedical engineering at the Israel Institute of Technology (Technion; Haifa, Israel). “We hope that one day it will have a positive impact on patients suffering from a range of medical crises resulting from blood clot occlusions.”
Related Links:
Wyss Institute for Biologically Inspired Engineering
New England Center for Stroke Research
Israel Institute of Technology
Latest Surgical Techniques News
- Easy-To-Apply Gel Could Prevent Formation of Post-Surgical Abdominal Adhesions
- Groundbreaking Leadless Pacemaker to Prevent Invasive Surgeries for Children
- Spectroscopy Technique Improves Surgery for Pediatric Epilepsy Patients
- Bioengineered Arteries Show Promise for Cardiovascular Surgery
- Online Tool Guides Surgical Decisions for Gallbladder Cancer
- Innovative Technology Enables Rapid Life-Saving Surgical Leak Detection
- First-Of-Its-Kind Bioresorbable Implant to Help Children with Rare Respiratory Disease
- Screw-Shaped Magnetic Microrobots to Transform Treatment for Patients with Inoperable Blood Clots
- "Ultra-Rapid" Testing in the OR Could Enable Accurate Removal of Brain Tumors
- Automated Endoscopic Device Obtains Improved Biopsy Results in Single Pass
- World's First Machine Learning Model Combats Wrong-Site Surgery
- Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk
- New Surface Coating Could Prevent Blood Clotting in Medical Devices and Implants
- Dumbbell-Shaped Thrombectomy Device Offers Novel Approach to Cerebral Venous Sinus Thrombosis Treatment
- Novel Catheter Mimics Snake Teeth to Grab Blood Clots
- New Laparoscopic Imaging Technique Accurately Maps Biological Tissue for Minimally Invasive Surgery
Channels
Artificial Intelligence
view channel
Innovative Risk Score Predicts Heart Attack or Stroke in Kidney Transplant Candidates
Heart researchers have utilized an innovative risk assessment score to accurately predict whether patients being evaluated for kidney transplants are at risk for future major cardiac events, such as a... Read more
AI Algorithm Detects Early-Stage Metabolic-Associated Steatotic Liver Disease Using EHRs
Liver disease, which is treatable when detected early, often goes unnoticed until it reaches advanced stages. Metabolic-associated steatotic liver disease (MASLD), the most prevalent form of liver disease,... Read moreCritical Care
view channel
Novel Coating Significantly Extends Longevity of Implantable Biosensors
Wearable and implantable biosensors capable of accurately detecting biological molecules in a non-invasive or minimally invasive way offer enormous potential for monitoring patients’ health and their responses... Read more
Nanogel-Based Drug Delivery Technology to Improve UTI Treatment
Urinary tract infections (UTIs) are not only widespread and costly but also highly debilitating, significantly impacting the quality of life for those affected. The antibiotics commonly used to treat UTIs... Read more
New IV Pole Improves Safety and Ease of Administering IV Medications at Hospital Bedside
Preventable medication errors affect around 500,000 hospitalized patients in the U.S. every year. A significant portion of these errors occur with intravenous (IV) smart pumps, which require a precise... Read morePatient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read morePoint of Care
view channel
Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour
Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing
Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. This is especially valuable in remote or underserved regions where... Read moreBusiness
view channel
Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA), has announced that its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic... Read more